Eczema Area and Severity Index (EASI)

EASI is an investigator‑rated score quantifying atopic dermatitis severity by combining lesion intensity and affected body area 1 [Level II evidence].

Head/neck redness
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Head/neck thickness
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Head/neck scratching (excoriation)
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Head/neck lichenification
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Percentage of head/neck affected
0%01-9%+110-29%+230-49%+350-69%+470-89%+590-100%+6
Upper limbs redness
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Upper limbs thickness
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Upper limbs scratching
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Upper limbs lichenification
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Percentage of upper limbs affected
0%01-9%+110-29%+230-49%+350-69%+470-89%+590-100%+6
Trunk redness
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Trunk thickness
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Trunk scratching
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Trunk lichenification
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Percentage of trunk affected
0%01-9%+110-29%+230-49%+350-69%+470-89%+590-100%+6
Lower limbs redness
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Lower limbs thickness
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Lower limbs scratching
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Lower limbs lichenification
None, absent0Mild (just perceptable)+1Moderate (obvious)+2Severe+3
Percentage of lower limbs affected
0%01-9%+110-29%+230-49%+350-69%+470-89%+590-100%+6

Indications for Use

Used to quantify clinical signs of atopic dermatitis in trials and specialized care, especially when assessing treatment response and defining endpoints (EASI‑50/75/90). Supported as a core instrument for clinician‑reported signs by the HOME consensus 1 [Level I evidence]. Systematic reviews confirm strong validity, reliability, and sensitivity to change 2 [Level II evidence]; recommended for moderate–severe disease assessment and comparison across interventions.

Insights & Cautions

Start by noting it reliably captures objective clinical signs and is the HOME‑recommended core instrument with adequate validity and responsiveness 1 [Level I evidence]. It is observer‑dependent, time‑consuming, and shows high inter‑rater variability in some studies 2 [Level II evidence]. Sensitivity is good but floor effects limit use in mild disease 3 [Level II evidence]. Caution in skin of color due to limited validation 4 [Level III evidence].